[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Kanamori M, Suzuki H, Sato I, Ohyama K, Tezuka F, Katakura R: A case of idiopathic hypereosinophilic syndrome with leptomeningeal dissemination and intraventricular mass lesion: an autopsy report. Clin Neuropathol; 2009 May-Jun;28(3):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 43-year-old female presented with idiopathic hypereosinophilic syndrome (HES) manifesting as an intraventricular mass lesion and leptomeningeal and cerebral parenchymal infiltration by eosinophils, lymphocytes and macrophages.
  • Magnetic resonance imaging revealed a mass lesion in the right lateral ventricle and leptomeningeal involvement around the brain stem.
  • Autopsy demonstrated significant infiltration by eosinophils and lymphocytes into the mass lesion in the ventricle, subarachnoid space, perivascular space and parenchyma of the medulla oblongata.
  • The present case shows that leptomeningeal dissemination and infiltration by eosinophils into the cerebral ventricles and brain stem should be considered in the course of idiopathic HES.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Autopsy. Fatal Outcome. Female. Humans. Immunohistochemistry. Otitis Media / drug therapy. Otitis Media / etiology. Radiotherapy


2. Adolph MD, Stretanski MF, McGregor JM, Rawn BL, Ross PM, Benedetti C: Intracerebroventricular morphine for refractory cancer pain: transitioning to the home setting. Am J Hosp Palliat Care; 2010 Aug;27(5):326-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebroventricular morphine for refractory cancer pain: transitioning to the home setting.
  • Refractory cancer pain may be effectively controlled by titrating intracerebroventricular (ICV) preservative-free opioid.
  • In this case report, a continuous infusion of ICV morphine permitted our patient with lung cancer and painful spinal metastases to be discharged to home hospice with family.
  • Sterile, injectable, preservative-free morphine is directly infused into CSF through a subcutaneous Ommaya reservoir placed under the scalp by a neurosurgeon, with an attached catheter passed through a burr hole in the skull with its tip in a cerebral ventricle.
  • [MeSH-major] Analgesics, Opioid / administration & dosage. Infusion Pumps, Implantable. Morphine / administration & dosage. Pain, Intractable / drug therapy. Palliative Care / methods
  • [MeSH-minor] Dose-Response Relationship, Drug. Drug Administration Schedule. Fatal Outcome. Female. Humans. Injections, Intraventricular. Lung Neoplasms / complications. Middle Aged

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103784.001).
  • [ISSN] 1938-2715
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


3. Wisse BE, Frayo RS, Schwartz MW, Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology; 2001 Aug;142(8):3292-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of cancer anorexia by blockade of central melanocortin receptors in rats.
  • The etiology of cancer anorexia is poorly understood, and effective treatment options are limited.
  • To investigate the role of central melanocortin receptor signaling in the pathogenesis of cancer anorexia, we assessed the effects on food intake of the melanocortin receptor antagonist SHU9119 administered into the third cerebral ventricle of Lobund-Wistar rats that were anorexic from prostate cancer.
  • In control rats pair-fed to the intake of tumor-bearing animals, SHU9119 was ineffective at increasing food intake.
  • Because SHU9119 completely reverses cancer anorexia in this model, whereas ghrelin and NPY do not, increased central nervous system melanocortin signaling is implicated in the pathogenesis of this disorder.
  • This suggests that new targets for the treatment of cancer anorexia may be found in the melanocortin pathways.
  • [MeSH-major] Adenocarcinoma / complications. Anorexia / drug therapy. Anorexia / etiology. Brain / metabolism. Melanocyte-Stimulating Hormones / therapeutic use. Peptide Hormones. Prostatic Neoplasms / complications. Receptors, Corticotropin / antagonists & inhibitors
  • [MeSH-minor] Animals. Body Weight / drug effects. Eating / drug effects. Ghrelin. Injections, Intraventricular. Male. Neuropeptide Y / therapeutic use. Peptides / therapeutic use. Rats. Rats, Wistar. Receptors, Melanocortin. Reference Values. Third Ventricle

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11459770.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-35816; United States / NIDDK NIH HHS / DK / T32-DK-07247
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Neuropeptide Y; 0 / Peptide Hormones; 0 / Peptides; 0 / Receptors, Corticotropin; 0 / Receptors, Melanocortin; 168482-23-3 / SHU 9119; 9002-79-3 / Melanocyte-Stimulating Hormones
  •  go-up   go-down


Advertisement
4. Stiefel M, Reiss T, Staege MS, Rengelshausen J, Burhenne J, Wawer A, Foell JL: Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatr Blood Cancer; 2007 Aug;49(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive aspergillosis is an increasing problem in immuno-incompetent patients after prolonged steroid therapy, cancer radio-chemotherapy, and bone marrow or solid organ transplantation.
  • Cerebral aspergillosis is a well-described complication of the invasive aspergillosis but only in rare cases, the brain is the sole site of infection.
  • Despite increasing availability of antifungal drugs, the prognosis of cerebral aspergillosis is poor.
  • We report on an 11-year-old boy with medulloblastoma in the area of the fourth ventricle.
  • To improve treatment, voriconazole dosage was adapted to reach drug concentrations in cerebrospinal fluid (CSF) above the minimal fungicidal concentration and plasma specimens.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillus fumigatus. Brain Abscess / drug therapy. Cerebral Ventricle Neoplasms / complications. Medulloblastoma / complications. Neuroaspergillosis / drug therapy. Pyrimidines / therapeutic use. Surgical Wound Infection / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Child. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Cyclophosphamide / administration & dosage. Diagnostic Errors. Etoposide / administration & dosage. Humans. Immunocompromised Host. Infusions, Intravenous. Lomustine / administration & dosage. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local / diagnosis. Vincristine / administration & dosage. Voriconazole

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333861.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; JFU09I87TR / Voriconazole; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Ginguené C, Champier J, Maallem S, Strazielle N, Jouvet A, Fèvre-Montange M, Ghersi-Egea JF: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol; 2010 Sep;20(5):926-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
  • Ependymomas are neuroepithelial tumors that arise from the ependymal layer bordering the cerebral ventricles and spinal canal.
  • To understand the pharmacoresistance that characterizes this tumoral entity, we analyzed the level of expression and localization of three major efflux transport proteins with a multidrug resistance function, P-glycoprotein, multidrug resistance-related protein 1 (MRP1) and breast cancer resistance protein (BCRP), in a series of 25 ependymomas from both children and adults.
  • The expression of the proteins corresponding to these genes was confirmed by Western blot analysis.
  • In an immunohistochemical study, P-glycoprotein and BCRP were shown to be associated with the tumoral vessels, where they presented a luminal localization, a prerequisite for their efflux drug activity into the blood.
  • These data indicate that a biochemical, transporter-dependent blood-tumor barrier may exist in ependymomas, which may reduce the tumoral bioavailability of lipophilic and amphiphilic anticancer drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Blood-Testis Barrier / metabolism. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Microvessels / metabolism. Neoplasm Proteins / metabolism. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adolescent. Adult. Aged. Child. Child, Preschool. Humans. Infant. Laminin / metabolism. Middle Aged. Models, Biological. Young Adult. von Willebrand Factor / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406235.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Laminin; 0 / Neoplasm Proteins; 0 / von Willebrand Factor
  •  go-up   go-down


6. Furne C, Ricard J, Cabrera JR, Pays L, Bethea JR, Mehlen P, Liebl DJ: EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. Biochim Biophys Acta; 2009 Feb;1793(2):231-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, infusion of soluble ephrinB3 into the lateral ventricle reduced cell death, and together these results support a dependence role for EphA4 in adult neurogenesis.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5181-7 [16033834.001]
  • [Cites] J Neurosci. 2007 Dec 26;27(52):14392-403 [18160647.001]
  • [Cites] J Neurosci Res. 2000 Jun 1;60(5):587-93 [10820429.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4791-805 [10848605.001]
  • [Cites] Nat Neurosci. 2000 Nov;3(11):1091-7 [11036265.001]
  • [Cites] Cell. 2001 Sep 21;106(6):745-57 [11572780.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Science. 2003 Aug 8;301(5634):843-6 [12907805.001]
  • [Cites] J Neurosci. 2003 Dec 3;23(35):11112-9 [14657169.001]
  • [Cites] Apoptosis. 2004 Jan;9(1):37-49 [14739597.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Physiol Rev. 2004 Apr;84(2):411-30 [15044679.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 11;318(4):882-92 [15147954.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):464-71 [15173825.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32643-50 [15145949.001]
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):749-55 [15258591.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):979-83 [15300251.001]
  • [Cites] Nature. 2004 Sep 2;431(7004):80-4 [15343335.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1061-5 [9185712.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10328-39 [15542841.001]
  • [Cites] Genes Dev. 2005 Feb 15;19(4):462-71 [15713841.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75 [15928710.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1244-50 [15902206.001]
  • [Cites] Mol Cell Neurosci. 2006 Apr;31(4):713-22 [16483793.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8943-8 [16982731.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1211-6 [16965393.001]
  • [Cites] PLoS One. 2007;2(5):e463 [17520022.001]
  • [Cites] Cell Death Differ. 2005 Dec;12(12):1601-12 [15947791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13361-6 [17686986.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):454-64 [16272170.001]
  • (PMID = 18948148.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS049545-01A1; United States / NINDS NIH HHS / NS / NS049545-01A1; United States / NINDS NIH HHS / NS / NS049545-03; United States / NINDS NIH HHS / NS / NS30291; United States / NINDS NIH HHS / NS / NS049545-02; United States / NINDS NIH HHS / NS / R01 NS051709; United States / NINDS NIH HHS / NS / R01 NS049545-03; United States / NINDS NIH HHS / NS / R01 NS049545; United States / NINDS NIH HHS / NS / R01 NS049545-02; United States / NINDS NIH HHS / NS / NS049545-04; United States / NINDS NIH HHS / NS / NS049545; United States / NINDS NIH HHS / NS / R01 NS049545-04; United States / NINDS NIH HHS / NS / P50 NS030291
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ephrin-B3; 0 / Ligands; EC 2.7.10.1 / Receptor, EphA4; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS76055; NLM/ PMC2631096
  •  go-up   go-down


7. Salzer W, Widemann B, McCully C, Adamson PC, Balis FM: Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. Cancer Chemother Pharmacol; 2001 Sep;48(3):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nonhuman primates (Macaca mulatta) with permanently implanted catheters in the lateral and fourth ventricles received 0.5 mg intraventricular (lateral ventricle) MTX, or 0.5 mg intralumbar MTX with and without intralumbar or intravenous probenecid.
  • Animals were kept prone for 1 h after MTX administration, and ventricular CSF was sampled up to 48 h from a fourth ventricular Ommaya reservoir.
  • Asymptomatic pleocytosis was observed in all animals after intralumbar probenecid administration.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Cerebrospinal Fluid / metabolism. Methotrexate / pharmacokinetics. Probenecid / pharmacology. Uricosuric Agents / pharmacology
  • [MeSH-minor] Animals. Area Under Curve. Cerebral Ventricles / metabolism. Drug Administration Routes. Infusions, Intravenous. Injections, Intraventricular. Injections, Spinal. Lumbosacral Region. Macaca mulatta. Toxicity Tests

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROBENECID .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11592346.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Uricosuric Agents; PO572Z7917 / Probenecid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Nagaraja TN, Patel P, Gorski M, Gorevic PD, Patlak CS, Fenstermacher JD: In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res; 2005 Jul 26;2:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Putatively active drugs are often intraventricularly administered to gain direct access to brain and circumvent the blood-brain barrier.
  • In this study, we report the intracranial distribution and the clearance from CSF and adjacent CNS tissue of radiolabeled insulin-like growth factor-1 after injection into one lateral ventricle of the normal rat brain.
  • METHODS: Under barbiturate anesthesia, 125I-labeled insulin-like growth factor-1 (IGF-1) was injected into one lateral ventricle of normal Sprague-Dawley rats.
  • The subsequent distribution of IGF-1 through the cerebrospinal fluid (CSF) system and into brain, cerebral blood vessels, and systemic blood was measured over time by gamma counting and quantitative autoradiography (QAR).
  • RESULTS: Within 5 min of infusion, IGF-1 had spread from the infused lateral ventricle into and through the third and fourth ventricles.
  • CONCLUSION: Our findings suggest that entry of IGF-1 into normal brain parenchyma after lateral ventricle administration is limited by rapid clearance from CSF and brain and slow movement, apparently by diffusion, into the periventricular tissue.
  • Various growth factors and other neuroactive agents have been reported to be neuroprotective within the injured brain after intraventricular administration.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 1999 Mar;89(3):649-59 [10199602.001]
  • [Cites] Brain Res Bull. 1999 Jul 1;49(4):221-43 [10424843.001]
  • [Cites] Brain Res. 2000 Jan 24;853(2):163-73 [10640614.001]
  • [Cites] Brain Res. 2000 Mar 24;859(2):286-92 [10719076.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Mar;20(3):513-9 [10724116.001]
  • [Cites] J Clin Invest. 2000 Dec;106(12):1489-99 [11120756.001]
  • [Cites] Microcirculation. 2001 Dec;8(6):365-75 [11781810.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):629-34 [11826091.001]
  • [Cites] Am J Physiol. 1975 Oct;229(4):877-84 [1190330.001]
  • [Cites] Neuroscience. 1992;46(4):909-23 [1311816.001]
  • [Cites] J Appl Physiol (1985). 1992 Sep;73(3):918-24 [1400056.001]
  • [Cites] Am J Physiol. 1991 Aug;261(2 Pt 2):R265-75 [1877685.001]
  • [Cites] Mol Endocrinol. 1990 May;4(5):773-8 [2177145.001]
  • [Cites] Trends Neurosci. 1988 Mar;11(3):107-11 [2465607.001]
  • [Cites] Ann N Y Acad Sci. 1988;531:29-39 [3382143.001]
  • [Cites] Am J Physiol. 1987 Mar;252(3 Pt 1):E299-303 [3548427.001]
  • [Cites] J Endocrinol. 1995 Jul;146(1):141-8 [7561610.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1995 May;111(1):1-15 [7749630.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):556-63; discussion 563-4 [7753356.001]
  • [Cites] Trends Neurosci. 1995 Mar;18(3):143-50 [7754526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] J Appl Physiol. 1976 Mar;40(3):458-63 [819414.001]
  • [Cites] J Cereb Blood Flow Metab. 1993 Jul;13(4):609-16 [8314914.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3752-7 [8339287.001]
  • [Cites] J Cereb Blood Flow Metab. 1993 Sep;13(5):895-8 [8360296.001]
  • [Cites] J Clin Invest. 1996 Jan 15;97(2):300-8 [8567948.001]
  • [Cites] Endocrinology. 1996 Mar;137(3):893-8 [8603600.001]
  • [Cites] Neuroreport. 1996 Jan 31;7(2):632-6 [8730846.001]
  • [Cites] J Neurochem. 1996 Aug;67(2):880-3 [8764620.001]
  • [Cites] Peptides. 1996;17(2):247-50 [8801529.001]
  • [Cites] Neuropathol Appl Neurobiol. 1996 Aug;22(4):325-33 [8875467.001]
  • [Cites] Neuroscience. 1996 Dec;75(4):1271-88 [8938759.001]
  • [Cites] Trends Neurosci. 1997 Aug;20(8):326-31 [9246719.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31 [9270488.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jan;284(1):111-5 [9435168.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):734-42 [9525721.001]
  • [Cites] Brain Res. 1998 Apr 20;790(1-2):115-28 [9593852.001]
  • [Cites] Trends Neurosci. 1998 May;21(5):207-15 [9610885.001]
  • [Cites] Stroke. 1998 Jul;29(7):1411-5; discussion 1416 [9660397.001]
  • (PMID = 16045806.001).
  • [ISSN] 1743-8454
  • [Journal-full-title] Cerebrospinal fluid research
  • [ISO-abbreviation] Cerebrospinal Fluid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1190198
  •  go-up   go-down


9. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, Faria MC, Velloso LA, Saad MJ, Carvalheira JB: A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia. Endocrinology; 2007 Nov;148(11):5220-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia.
  • The pathogenesis of cancer anorexia is multifactorial and associated with disturbances of the central physiological mechanisms controlling food intake.
  • However, the neurochemical mechanisms responsible for cancer-induced anorexia are unclear.
  • Here we show that chronic infusion of 5-amino-4imidazolecarboxamide-riboside into the third cerebral ventricle and a chronic peripheral injection of 2 deoxy-d-glucose promotes hypothalamic AMP-activated protein kinase (AMPK) activation, increases food intake, and prolongs the survival of anorexic tumor-bearing (TB) rats.
  • In parallel, the pharmacological activation of hypothalamic AMPK in TB animals markedly reduced the hypothalamic production of inducible nitric oxide synthase, IL-1beta, and TNF-alpha and modulated the expression of proopiomelanocortin, a hypothalamic neuropeptide that is involved in the control of energy homeostasis.
  • Furthermore, the daily oral and intracerebroventricular treatment with biguanide antidiabetic drug metformin also induced AMPK phosphorylation in the central nervous system and increased food intake and life span in anorexic TB rats.
  • Collectively, the findings of this study suggest that hypothalamic AMPK activation reverses cancer anorexia by inhibiting the production of proinflammatory molecules and controlling the neuropeptide expression in the hypothalamus, reflecting in a prolonged life span in TB rats.
  • Thus, our data indicate that hypothalamic AMPK activation presents an attractive opportunity for the treatment of cancer-induced anorexia.
  • [MeSH-minor] AMP-Activated Protein Kinases. Aminoimidazole Carboxamide / administration & dosage. Aminoimidazole Carboxamide / analogs & derivatives. Aminoimidazole Carboxamide / pharmacology. Animals. Deoxyglucose / administration & dosage. Deoxyglucose / pharmacology. Drug Administration Routes. Hypothalamus / drug effects. Hypothalamus / enzymology. Hypothalamus / metabolism. Male. Metformin / administration & dosage. Metformin / pharmacology. Neoplasm Transplantation. Phosphorylation. Rats. Rats, Wistar. Ribonucleotides / administration & dosage. Ribonucleotides / pharmacology. Survival Analysis. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717055.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; 0 / Ribonucleotides; 360-97-4 / Aminoimidazole Carboxamide; 9100L32L2N / Metformin; 9G2MP84A8W / Deoxyglucose; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; F0X88YW0YK / AICA ribonucleotide
  •  go-up   go-down


10. Rook J, Rosser T, Fangusaro J, Finlay J: Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatr Blood Cancer; 2008 Mar;50(3):699-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Brain Diseases / chemically induced. Cerebral Ventricle Neoplasms / drug therapy. Cerebral Ventricle Neoplasms / secondary. Germinoma / drug therapy. Germinoma / secondary. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / adverse effects. Pituitary Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16991134.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04079A1RDZ / Cytarabine; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG: Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol; 2000;45(3):259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Intrathecal methotrexate achieves high concentrations in cerebrospinal fluid (CSF), but drug distribution throughout the subarachnoid space after an intralumbar dose is limited.
  • METHODS: Nonhuman primates (Macaca mulatta) with permanently implanted catheters in the lateral and fourth ventricles received methotrexate by bolus injection (0.5 mg) and infusion (0.05 to 0.5 mg/day over 24 to 168 h) into the lateral ventricle, as well as intravenous infusions.
  • CSF was sampled from the lumbar space, fourth ventricle and the subarachnoid space at the vertex.
  • RESULTS: After bolus intraventricular injection, methotrexate exposure in lumbar CSF ranged from 11% to 69% of that achieved in the fourth ventricle.
  • The dose, duration of infusion, and infusate volume did not influence drug distribution to the lumbar CSF, but probenicid increased the lumbar to ventricular C(ss) ratio, suggesting the involvement of a probenicid-sensitive transport pump in the efflux of MTX from the CSF.
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Cerebral Ventricles / drug effects. Dose-Response Relationship, Drug. Infusions, Intravenous. Infusions, Parenteral. Injections, Intraventricular. Macaca mulatta. Male. Metabolic Clearance Rate. Probenecid / pharmacology. Uricosuric Agents / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROBENECID .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10663645.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Uricosuric Agents; PO572Z7917 / Probenecid; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Zhang YM, Wei EQ, Hu X, Qiao WL, Shi Y, Xu M, Zhang JF: The role of nuclear factor-kappaB in the effect of angiotensin II in the paraventricular nucleus in protecting the gastric mucosa from ischemia-reperfusion injury in rats. J Gastroenterol; 2008;43(9):687-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of Ang II were prevented by pretreatment with the Ang II AT1 receptor antagonist losartan (5 microg) microinjected into the lateral cerebral ventricle.
  • [MeSH-major] Angiotensin II / pharmacology. Gastric Mucosa / blood supply. NF-kappa B / physiology. Paraventricular Hypothalamic Nucleus / drug effects. Reperfusion Injury / prevention & control
  • [MeSH-minor] Angiotensin II Type 1 Receptor Blockers / pharmacology. Animals. Dose-Response Relationship, Drug. I-kappa B Proteins / metabolism. Losartan / pharmacology. Male. Malondialdehyde / metabolism. NF-KappaB Inhibitor alpha. Phosphorylation. Pyrrolidines / pharmacology. Rats. Rats, Sprague-Dawley. Regional Blood Flow. Superoxide Dismutase / metabolism. Thiocarbamates / pharmacology

  • Hazardous Substances Data Bank. Losartan .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):874-81 [17352016.001]
  • [Cites] Can J Physiol Pharmacol. 2005 Jun;83(6):483-92 [16049548.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):413-9 [14683469.001]
  • [Cites] Brain Res. 2002 Apr 12;933(1):23-30 [11929632.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Clin Chem. 1988 Mar;34(3):497-500 [3349599.001]
  • [Cites] Nature. 1997 Feb 6;385(6616):540-4 [9020361.001]
  • [Cites] Semin Cancer Biol. 1997 Apr;8(2):63-73 [9299584.001]
  • [Cites] Endocrinology. 1988 Jan;122(1):370-2 [3335214.001]
  • [Cites] Life Sci. 2002 Aug 16;71(13):1501-10 [12127905.001]
  • [Cites] J Psychiatr Res. 1988;22(1):35-42 [3294384.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jun;280(6):G1296-304 [11352824.001]
  • [Cites] Eur J Pharmacol. 2001 Jul 13;424(1):69-74 [11470262.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Feb;226(2):85-96 [11446443.001]
  • [Cites] Neuroendocrinology. 2002 Apr;75(4):227-40 [11979053.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):G1024-30 [9696701.001]
  • [Cites] Pharmacology. 1997 Sep;55(3):154-64 [9346404.001]
  • [Cites] Life Sci. 2001 Feb 9;68(12):1405-15 [11388692.001]
  • [Cites] Annu Rev Neurosci. 1983;6:269-324 [6132586.001]
  • [Cites] Circ Res. 2003 Feb 21;92 (3):293-9 [12595341.001]
  • [Cites] Stress. 2007 Jun;10(2):185-93 [17514587.001]
  • [Cites] Life Sci. 1997;60(8):PL127-33 [9042393.001]
  • [Cites] Eur J Pharmacol. 2003 Dec 15;482(1-3):271-80 [14660032.001]
  • [Cites] Life Sci. 1996;59(19):PL295-301 [8913334.001]
  • [Cites] Brain Res. 1985 Mar 11;329(1-2):374-8 [3978460.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4368-76 [15383566.001]
  • [Cites] Cell. 1997 Oct 17;91(2):243-52 [9346241.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L528-36 [10956628.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G713-21 [12466147.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2007 Aug;34(8):742-52 [17600551.001]
  • [Cites] Am J Surg. 1996 Aug;172(2):158-61; discussion 161-2 [8795521.001]
  • [Cites] Hypertension. 2002 Jun;39(6):1101-6 [12052849.001]
  • [Cites] J Neurochem. 2004 Nov;91(3):755-65 [15485504.001]
  • [Cites] Stroke. 2004 Apr;35(4):987-91 [14988572.001]
  • [Cites] Brain Res. 1997 Jul 4;761(2):203-9 [9252017.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1158-68 [17287895.001]
  • [Cites] Cell Mol Neurobiol. 2005 Jun;25(3-4):485-512 [16075377.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16518-23 [2777795.001]
  • [Cites] J Neurosci Res. 1997 Sep 15;49(6):681-97 [9335256.001]
  • [Cites] Eur J Pharmacol. 2000 Jun 9;398(1):147-58 [10856459.001]
  • [Cites] Circulation. 2001 May 8;103(18):2296-302 [11342480.001]
  • [Cites] J Physiol Pharmacol. 2002 Mar;53(1):39-50 [11939718.001]
  • [Cites] Anal Biochem. 1966 Aug;16(2):359-64 [6007581.001]
  • [Cites] Prog Neurobiol. 1998 Feb;54(2):169-92 [9481797.001]
  • [Cites] Gastroenterology. 1979 Jan;76(1):88-93 [361495.001]
  • [Cites] Epilepsia. 2006 Feb;47(2):233-9 [16499746.001]
  • [Cites] Front Neuroendocrinol. 1997 Oct;18(4):383-439 [9344632.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 1):G48-54 [8304457.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jun;35(6):901-18 [12676175.001]
  • [Cites] Pharmacology. 2001 May;62(4):200-7 [11359995.001]
  • (PMID = 18807130.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Nfkbia protein, rat; 0 / Pyrrolidines; 0 / Thiocarbamates; 11128-99-7 / Angiotensin II; 139874-52-5 / NF-KappaB Inhibitor alpha; 25769-03-3 / pyrrolidine dithiocarbamic acid; 4Y8F71G49Q / Malondialdehyde; EC 1.15.1.1 / Superoxide Dismutase; JMS50MPO89 / Losartan
  •  go-up   go-down


13. Hide T, Kuratsu J: [Progress in the study of brain tumor stem cells as treatment targets]. Brain Nerve; 2009 Jul;61(7):781-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study of cancer stem cells (CSCs) is on the cutting edge of cancer research.
  • Following the discovery of neural stem cells (NSCs), extensive studies on their characteristics led to the discovery of cancer stem cells (CSCs) in brain tumors: these cells are termed brain tumor stem cells (BTSCs).
  • Adult NSCs exist in the subventricular zone (SVZ) of the lateral ventricle and in the subgranular zone (SGZ) of the hippocampal dentate gyrus.
  • Glioblastoma multiforme (GBM) is one of the most malignant forms of human cancer.
  • Early cancer therapies for GBM primarily targeted the rapidly-dividing cells and not the slowly-dividing cells, which were minor populations of cells containing BTSCs.
  • Moreover, treatment with drugs that affect the stem cell niche in brain tumor-bearing mice prolonged their survival.
  • [MeSH-minor] Adult. Animals. Cerebral Ventricles / cytology. Dentate Gyrus / cytology. Hippocampus / cytology. Humans. Mice. Stem Cell Niche / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618855.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 35
  •  go-up   go-down


14. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, Albrecht S, Hiner RL, Gall S, Huse JT, Jabado N, MacDonald TJ, Holland EC: Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res; 2010 Mar 15;70(6):2548-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that the likely cells of origin for these mouse BSGs exist on the floor of the fourth ventricle and cerebral aqueduct.
  • This PDGF-induced BSG model can serve as a preclinical tool for the testing of novel agents.
  • [MeSH-major] Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Disease Models, Animal. Glioma / drug therapy. Glioma / radiotherapy. Phosphorylcholine / analogs & derivatives
  • [MeSH-minor] Animals. Combined Modality Therapy. Genetic Engineering. Inbreeding. Mice. Mice, Inbred BALB C. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Acta Neuropathol. 1996 Jul;92(1):90-7 [8811130.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64 [10192340.001]
  • [Cites] Indian J Cancer. 2004 Oct-Dec;41(4):170-4 [15659871.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):241-8 [16510333.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • [Cites] Childs Nerv Syst. 2006 Dec;22(12):1519-25 [17021732.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1 Suppl):1-4 [17647306.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):436-48 [18281460.001]
  • [Cites] J Neurooncol. 2008 May;87(3):247-53 [18193393.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3386-94 [18519768.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):566-72 [18484645.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):849-55 [18976074.001]
  • [Cites] Br J Neurosurg. 2008 Oct;22(5):619-24 [19016112.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):113-23 [17327574.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3027-36 [18802038.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Neurosurgery. 2009 Mar;64(3):455-61; discussion 461-2 [19240607.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2342-51 [19362466.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):151-9 [19585223.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):375-82; discussion 382 [12968803.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15 [8103086.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Oct 29;196(2):851-7 [8240361.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):1026-9; discussion 1029-30 [8133987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • (PMID = 20197468.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100688; United States / NCI NIH HHS / CA / R01 CA100688; United States / NCI NIH HHS / CA / U01 CA141502; United States / NCI NIH HHS / CA / U01 CA141502; United States / NCI NIH HHS / CA / U54 CA126518; United States / NCI NIH HHS / CA / U54 CA126518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS171774; NLM/ PMC3831613
  •  go-up   go-down


15. Theus MH, Ricard J, Bethea JR, Liebl DJ: EphB3 limits the expansion of neural progenitor cells in the subventricular zone by regulating p53 during homeostasis and following traumatic brain injury. Stem Cells; 2010 Jul;28(7):1231-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lateral ventricle infusion of soluble preclustered ephrinB3-Fc reversed the proliferative and cell death defects in ephrinB3(-/-) but not EphB3(-/-) mice and prevented TBI-induced proliferation in wild-type NSPCs.
  • Furthermore, pharmacological inhibition and siRNA knockdown of p53-attenuated ephrinB3-Fc-mediated growth suppression while having no effect on cell death in cultured NSPCs.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2001 Jan;29(1):85-97 [11182083.001]
  • [Cites] IUBMB Life. 2004 May;56(5):257-65 [15370889.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] J Neurosci. 1993 Apr;13(4):1730-50 [8463848.001]
  • [Cites] Science. 1994 May 20;264(5162):1145-8 [8178174.001]
  • [Cites] EMBO J. 1994 Aug 15;13(16):3757-62 [8070404.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1541-2 [8079167.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] Curr Biol. 1996 Feb 1;6(2):108-10 [8673449.001]
  • [Cites] Cell. 1996 Jul 12;86(1):35-46 [8689685.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6035-49 [8947026.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14895-900 [8962152.001]
  • [Cites] Int J Dev Neurosci. 1996 Nov;14(7-8):921-30 [9010735.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] J Neurosci. 1997 Aug 1;17(15):5820-9 [9221780.001]
  • [Cites] Biochim Biophys Acta. 2009 Feb;1793(2):231-8 [18948148.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4172-88 [19339612.001]
  • [Cites] Brain Res. 2009 Jul 14;1280:172-7 [19464272.001]
  • [Cites] Brain Res. 2009 Sep 1;1287:157-63 [19573519.001]
  • [Cites] Development. 2010 Jan;137(2):313-21 [20040497.001]
  • [Cites] Neurobiol Dis. 2010 Feb;37(2):267-74 [19909815.001]
  • [Cites] J Histochem Cytochem. 2010 Mar;58(3):265-75 [19901272.001]
  • [Cites] J Cereb Blood Flow Metab. 2010 May;30(5):1008-16 [20068579.001]
  • [Cites] J Comp Neurol. 1966 Mar;126(3):337-89 [5937257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5874-9 [11320217.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2715-22 [11387206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 [11504915.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Ann Neurol. 2001 Nov;50(5):602-11 [11706966.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2738-46 [11709443.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):973-82 [11715018.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):629-34 [11826091.001]
  • [Cites] Neoplasia. 2002 Jan-Feb;4(1):82-7 [11922394.001]
  • [Cites] Curr Opin Neurobiol. 2002 Jun;12(3):250-9 [12049930.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):311-9 [12163450.001]
  • [Cites] Cell. 2002 Aug 23;110(4):429-41 [12202033.001]
  • [Cites] Nat Med. 2002 Sep;8(9):963-70 [12161747.001]
  • [Cites] Trends Biochem Sci. 2002 Sep;27(9):462-7 [12217521.001]
  • [Cites] Neuron. 2002 Dec 19;36(6):1021-34 [12495619.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):223-9 [12514219.001]
  • [Cites] J Neurochem. 2003 Nov;87(3):586-97 [14535942.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1202-10 [14561705.001]
  • [Cites] J Neurotrauma. 2003 Nov;20(11):1147-62 [14651803.001]
  • [Cites] Apoptosis. 2004 Jan;9(1):37-49 [14739597.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] J Neurotrauma. 2004 Mar;21(3):283-92 [15115603.001]
  • [Cites] Stroke. 2004 Jul;35(7):1732-7 [15178821.001]
  • [Cites] Cell Mol Life Sci. 2004 Aug;61(15):1854-66 [15289929.001]
  • [Cites] Exp Cell Res. 1999 Dec 15;253(2):733-6 [10585297.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):G824-32 [9357823.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 2):H331-41 [9458884.001]
  • [Cites] Oncogene. 1998 Jan 29;16(4):471-80 [9484836.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Sci Am. 1999 May;280(5):48-53 [10231988.001]
  • [Cites] Exp Neurol. 1999 Apr;156(2):333-44 [10328940.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10328-39 [15542841.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):978-87 [15573119.001]
  • [Cites] Curr Mol Med. 2004 Nov;4(7):741-51 [15579021.001]
  • [Cites] Genes Dev. 2005 Feb 15;19(4):462-71 [15713841.001]
  • [Cites] Physiol Genomics. 2005 Apr 14;21(2):152-60 [15671251.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):828-33 [15865938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9353-8 [15961540.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1244-50 [15902206.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1057-65 [15818407.001]
  • [Cites] Brain Res. 2005 Aug 16;1053(1-2):38-53 [16051202.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1089-100 [16319719.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] J Neurosci. 2006 Jan 18;26(3):882-92 [16421308.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1269-74 [16436614.001]
  • [Cites] Biol Cell. 2006 Mar;98(3):141-52 [16480340.001]
  • [Cites] Mol Cell Neurosci. 2006 Apr;31(4):713-22 [16483793.001]
  • [Cites] J Neurosci. 2006 Jun 14;26(24):6627-36 [16775151.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(1):45-54 [16882007.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1477-97 [16939970.001]
  • [Cites] Brain Res Rev. 2006 Sep;52(2):327-45 [16774788.001]
  • [Cites] Exp Neurol. 2006 Nov;202(1):189-99 [16876159.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):169-81, xi [17244562.001]
  • [Cites] J Neurosci Res. 2007 Mar;85(4):740-7 [17243175.001]
  • [Cites] Science. 2007 Mar 2;315(5816):1243-9 [17303719.001]
  • [Cites] J Neurosci. 2007 Mar 21;27(12):3157-62 [17376977.001]
  • [Cites] PLoS One. 2007;2(5):e463 [17520022.001]
  • [Cites] Neurochem Int. 2007 Jun;50(7-8):1028-41 [17531349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13361-6 [17686986.001]
  • [Cites] J Biosci. 2007 Aug;32(5):991-7 [17914240.001]
  • [Cites] Brain Res. 2007 Dec 14;1185:301-12 [17976541.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Mar;8(2):87-97 [18336191.001]
  • [Cites] Exp Neurol. 2008 Apr;210(2):656-70 [18279854.001]
  • [Cites] Cell. 2008 Apr 4;133(1):38-52 [18394988.001]
  • [Cites] Adv Exp Med Biol. 2008;615:201-21 [18441595.001]
  • [Cites] Cell Stem Cell. 2008 Sep 11;3(3):265-78 [18786414.001]
  • [Cites] Cell Stem Cell. 2008 Sep 11;3(3):289-300 [18786416.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1433-8 [10688783.001]
  • [Cites] Neuron. 2000 May;26(2):417-30 [10839360.001]
  • [Cites] Nat Neurosci. 2000 Nov;3(11):1091-7 [11036265.001]
  • (PMID = 20496368.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS064699; United States / NINDS NIH HHS / NS / F32 NS064699; United States / NINDS NIH HHS / NS / F32 NS064699-01A1; United States / NINDS NIH HHS / NS / NS30291; United States / NINDS NIH HHS / NS / R01 NS051709; United States / NINDS NIH HHS / NS / R01 NS049545; United States / NINDS NIH HHS / NS / T32 NS007459; United States / NINDS NIH HHS / NS / NS007459; United States / NINDS NIH HHS / NS / NS049545; United States / NINDS NIH HHS / NS / F32 NS064699-02; United States / NINDS NIH HHS / NS / NS064699-01A1; United States / NINDS NIH HHS / NS / P50 NS030291
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ephrin-B3; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, EphB3
  • [Other-IDs] NLM/ NIHMS243193; NLM/ PMC2967180
  •  go-up   go-down






Advertisement